JPRN-jRCT2080224598已完成1 期
A Phase I, Double-Blind, Randomized, Multicenter Trial of the Safety,Tolerability, and Immunogenicity of V114 in Healthy Japanese Infants
适应症
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 发起方
- MSD K.K.
- 入组人数
- 133
研究概览
简要总结
Vaccination with V114-SC or V114-IM at approximately 3, 4, 5 and 12 to 15 months of age in Japanese healthy infants is generally well tolerated, with safety profiles generally comparable to PCV13-SC.
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- >= 3month old 至 <= 3month old（—）
- 性别
- All
入选标准
- •1) Healthy (based on a review of medical history and physical examination) based on the clinical judgment of the investigator.
- •2) Male or female 3 months of age inclusive (3 months of age to1 day prior to 4 months of age), at the time of obtaining the informed consent.
- •3) Has a legally acceptable representative who understands the study procedures, alternate treatments available, and risks involved with the study and voluntarily agrees to participate by giving written informed consent.
排除标准
- •1)Has a history of invasive pneumococcal disease (positive blood culture, positive cerebrospinal fluid culture, or other sterile site) or known history of other culture positive pneumococcal disease.
- •2)Has a known hypersensitivity to vaccines, any component of the pneumococcal conjugate vaccine or any diphtheria toxoid-containing vaccine
- •3)Has any contraindication to the PCV13 and/or diphtheria, tetanus, acellular pertussis, inactivated polio vaccine (DTaP-IPV) being administered in the study (Refer to approved labeling for contraindication details on PCV13 and DTaPIPV vaccine).
- •4)Has a recent febrile illness (axillary temperature >= 37.5 degrees) occurring within 72 hours prior to receipt of study vaccine.
- •5)Has a known or suspected impairment of immunological function.
- •6)Has a history of congenital or acquired immunodeficiency.
- •7)Has or his/her mother has a documented hepatitis B surface antigen - positive test.
- •8)Has a known functional or anatomic asplenia.
- •9)Has failure to thrive based on the clinical judgement of the investigator.
- •10)Has thrombocytopenia or a known coagulation disorder contraindicating intramuscular vaccination.
- •11)Has a history of autoimmune disease (including but not limited to systemic lupus erythematosus, antiphospholipid syndrome, Bechet's disease, autoimmune thyroid disease, polymyositis and dermatomyositis, scleroderma, type 1 diabetes mellitus, or other autoimmune disorders).
- •12)Has a known neurologic or cognitive behavioral disorder, including encephalitis/myelitis, acute disseminating encephalomyelitis, pervasive development disorder, and related disorders.
- •13)Has received a dose of any pneumococcal and/or DTaP-IPV vaccine (or vaccine containing any DTaP-IPV component) prior to study entry.
- •14)Meets one or more of the following systemic corticosteroid exclusion criteria: has received systemic corticosteroids (equivalent of >= 2 mg/kg total daily dose of prednisone or >= 20 mg/d for persons weighing > 10 kg) for >= 14 consecutive days and has not completed this course of treatment at least 30 days prior to trial randomization, has received systemic corticosteroids within 14 days prior to the first dose of study vaccine at randomization, and is expected to require systemic corticosteroids (equivalent of >= 2 mg/kg total daily dose of prednisone or >= 20 mg/d for persons weighing > 10 kg) for >= 14 consecutive days within 14 days prior to or 30 days after each vaccination during conduct of the study.(Topical, ophthalmic and inhaled steroids are permitted.)
- •15)Has received other licensed non-live vaccines within the 14 days before receipt of first dose of study vaccine.
- •16)Has received a licensed live virus vaccine within the 28 days before receipt of first dose of study vaccine.
- •17)Has received a blood transfusion or blood products, including immunoglobulins before receipt of first dose of study vaccine.
- •18)Has participated in another clinical study of an investigational product before the beginning or anytime during the duration of the current clinical study. Participants enrolled in observational studies may be included; these will be reviewed on a case by case basis for approval by the Sponsor.
- •19)Has any other reason that, in the opinion of the investigator, may interfere with the evaluation required by the study. (Refer to the Vaccination Guideline in Japan). Reasons may include, but are not limited to, being unable to keep appointments or planning to relocate during the study.
- •20)Is or has an immediate
研究者
相似试验
已完成
3 期
A Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 in Children With Sickle Cell Disease (V114-023/PNEU-SICKLE)Pneumococcal InfectionsNCT03731182Merck Sharp & Dohme LLC104
已完成
1 期
Phase I/II clinical study of JVC-001Prevention of measles, mumps and rubellaJPRN-jRCT2080222978DAIICHI SANKYO Co.,Ltd.100
Unknown
4 期
Evaluation of Safety and Immunogenicity of Combined Immunization of sIPV, DTaP and HepAVaccinationNCT04636827China National Biotec Group Company Limited600
Unknown
4 期
Evaluation of Immunogenicity and Safety of Combined Immunization of sIPV, DTaP and MMRVaccineNCT04638985China National Biotec Group Company Limited600
已完成
2 期
A Dose-ranging Pediatric Study of an Adjuvanted Pandemic Influenza VaccineInfluenza, HumanNCT04669691Seqirus420